HWP
PFE icon

Highline Wealth Partners’s Pfizer PFE Stock Holding History

Highline Wealth Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.7K Sell
2,356
-784
-25% -$20.5K 0.01% 215
2026
Q1 		$88.2K Buy
3,140
+1,993
+174% +$53.1K 0.02% 125
2025
Q4 		$28.6K Buy
1,147
+178
+18% +$4.49K 0.01% 198
2025
Q3 		$24.7K Buy
969
+56
+6% +$1.38K 0.01% 240
2025
Q2 		$22.1K Sell
913
-550
-38% -$12.8K 0.01% 212
2025
Q1 		$37.1K Buy
1,463
+316
+28% +$8.27K 0.01% 151
2024
Q4 		$30.4K Sell
1,147
-39,454
-97% -$1.07M 0.01% 155
2024
Q3 		$1.17M Buy
40,601
+819
+2% +$23.9K 0.39% 52
2024
Q2 		$1.11M Buy
39,782
+1,268
+3% +$34.9K 0.42% 52
2024
Q1 		$1.07M Buy
38,514
+614
+2% +$17K 0.44% 54
2023
Q4 		$1.09M Buy
37,900
+2,763
+8% +$83.5K 0.53% 49
2023
Q3 		$1.17M Buy
35,137
+12
+0% +$424 0.72% 33
2023
Q2 		$1.29M Buy
35,125
+40
+0.1% +$1.56K 0.81% 35
2023
Q1 		$1.43M Buy
35,085
+959
+3% +$41.4K 0.98% 32
2022
Q4 		$1.75M Hold
34,126
– – 1.29% 24
2022
Q3 		$1.49M Buy
+34,126
New +$1.66M 1.21% 24

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Highline Wealth Partners's PFE Position: Q2 2026 in Review

Highline Wealth Partners reduced its Pfizer (PFE) stake by 25% in Q2 2026, selling an estimated $20.5K and leaving 2,356 shares worth $56.7K. The position accounts for 0.01% of the portfolio, ranked #215.

Highline Wealth Partners first reported a position in PFE in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.75M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Highline Wealth Partners held 2,356 shares of Pfizer worth $56.7K as of Q2 2026.
  • Highline Wealth Partners sold 784 Pfizer shares in Q2 2026, an estimated $20.5K.
  • Pfizer made up 0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #215 holding.
  • Highline Wealth Partners first reported a position in Pfizer in Q3 2022 and has held it in 16 quarters since.
  • Highline Wealth Partners's Pfizer position peaked at $1.75M in Q4 2022.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.